Diane Weiser
Senior Vice President, Corporate Affairs
Replay available
Cytokinetics, Incorporated (CYTK) Q4 2026 Earnings Call
Cytokinetics, Incorporated (NASDAQ: CYTK) Q4 2026 earnings conference call, held 2026-02-24. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Robert Blum
President and Chief Executive Officer
Andrew Kalos
Executive Vice President and Chief Commercial Officer
Stuart Kupfer
Senior Vice President and Chief Medical Officer
Sung Lee
Executive Vice President and Chief Financial Officer
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Cytokinetics, Incorporated.
Replay transcript excerpt
WEBVTT 00:00:00.031 -- 00:00:05.799 Thank you for standing by and welcome to the Cytokinetics fourth quarter 2025 00:00:05.799 -- 00:00:10.825 earnings call. This call is being recorded and all participants are in a listen 00:00:10.825 -- 00:00:16.052 only mode. After the speaker's remarks, we will open the call to questions. 00:00:16.052 -- 00:00:19.917 We will allow for one question per participant. 00:00:19.917 -- 00:00:24.102 If you would like to ask a question during this time, simply press star followed by the 00:00:24.102 -- 00:00:28.949 number one on your telephone keypad. And if you'd like to withdraw your question, press 00:00:28.949 -- 00:00:34.367 star one again. I would now like to turn the call over to Diane Weiser, 00:00:34.367 -- 00:00:38.513 Cytokinetics Senior Vice President of Corporate Affairs. 00:00:38.513 -- 00:00:41.094 Please go ahead. 00:00:41.177 -- 00:00:43.841 Good afternoon, and thanks for joining us on the call today. 00:00:43.841 -- 00:00:48.308 Robert Blum, President and Chief Executive Officer, will begin with an overview of the 00:00:48.308 -- 00:00:53.736 quarter and recent developments. Andrew Kalos, EVP and Chief Commercial Officer, 00:00:53.736 -- 00:00:56.640 will discuss the commercial launch of MyCorso in the U.S. 00:00:56.640 -- 00:01:01.911 and readiness in Europe. Patty Malek, EVP of R&D, and Stuart Kupfer, SVP 00:01:01.911 -- 00:01:07.516 and Chief Medical Officer, will provide updates related to our clinical development programs. 00:01:07.516 -- 00:01:12.541 Sung Lee, EVP and Chief Financial Officer, will provide a financial overview of 2025 00:01:12.541 -- 00:01:17.766 and discuss our 2026 financial guidance. And finally, Robert will then make closing 00:01:17.766 -- 00:01:21.389 remarks and review key milestones for the...